Efficacy, durability, and response predictors of low-dose interleukin-2 therapy for chronic graft-versus-host disease.
about
The CXCL10/CXCR3 Axis and Cardiac Inflammation: Implications for Immunotherapy to Treat Infectious and Noninfectious Diseases of the HeartRegulatory T Cell Responses in Participants with Type 1 Diabetes after a Single Dose of Interleukin-2: A Non-Randomised, Open Label, Adaptive Dose-Finding TrialAn activated Th17-prone T cell subset involved in chronic graft-versus-host disease sensitive to pharmacological inhibition.In vivo kinetics and nonradioactive imaging of rapidly proliferating cells in graft-versus-host diseaseIL-2 promotes early Treg reconstitution after allogeneic hematopoietic cell transplantation.Manipulation of Innate and Adaptive Immunity through Cancer Vaccines.IL-2, the next best thing in chronic GVHD therapy?Autophagy-dependent regulatory T cells are critical for the control of graft-versus-host disease.Low-dose IL-2 selectively activates subsets of CD4+ Tregs and NK cells.Tregs: hype or hope for allogeneic hematopoietic stem cell transplantation?Treg-Centric View of Immunosuppressive Drugs in Transplantation: A Balancing Act.Low-Dose IL-2 in the Treatment of Lupus.Chronic graft-versus-host disease: biological insights from preclinical and clinical studies.Mechanistic approaches for the prevention and treatment of chronic GVHD.Novel targets in the treatment of chronic graft-versus-host disease.Harnessing bone marrow resident regulatory T cells to improve allogeneic stem cell transplant outcomes.PD-1 modulates regulatory T-cell homeostasis during low-dose interleukin-2 therapy.Prophylactic use of low-dose interleukin-2 and the clinical outcomes of hematopoietic stem cell transplantation: A randomized study.Low-dose interleukin-2 as a modulator of Treg homeostasis after HSCT: current understanding and future perspectives.Efficacy and tolerance of ruxolitinib in refractory sclerodermatous chronic graft-versus-host disease.New and emerging therapies for acute and chronic graft versus host disease.Application of proteomics to graft-versus-host disease: from biomarker discovery to potential clinical applications.Low CD25 on autoreactive Tregs impairs tolerance via low dose IL-2 and antigen delivery.SJS/TEN 2017: Building Multidisciplinary Networks to Drive Science and Translation.Cytokine mediators of chronic graft-versus-host disease.Gene Therapy With Regulatory T Cells: A Beneficial Alliance.Advances in the Use of Regulatory T-Cells for the Prevention and Therapy of Graft-vs.-Host Disease.
P2860
Q28079006-3C2CD0CE-D372-4567-BF95-C111558194C1Q28554636-0D0FE98F-2D0F-413A-A79A-0EE4E89645AAQ33798102-3AB2C393-F5D8-4A88-8A2F-F616BFB84811Q33798249-CDD04750-40FD-48C2-B392-FC4A7FCFF98CQ33816022-FA7AFE25-F020-411D-8FC8-56D20625BA25Q34552791-6DBEFC2F-8A53-49E2-AC3A-AF6FA03F958CQ37076414-CA82C619-B319-4224-A432-C5717BBB34E3Q37277015-4E6C6A4E-4077-4F92-8F76-7B5058218527Q37377103-909858A3-BE58-45D8-9D38-F338122C6DBBQ38742863-32F78DC0-CF82-4E31-AEA1-7CBA62225469Q38942832-455C2D8B-02A2-4525-AEEE-0276639E511AQ38979253-D9633A36-E69F-48D2-A198-2CE27673C58BQ39002164-FE404CF8-71CF-47B5-BB81-E6C7EBC41D77Q39002166-E22A9DA2-DAF3-4583-BBE8-77B6304E897DQ39023963-F2C52B2F-BCB1-429E-B7C3-880A64CB57FCQ39036180-AA00F2C0-5314-4CF4-BDE5-60D3EFDAC398Q40354412-5F49310A-8F3E-4F5B-B73E-408C9A45B5B4Q42968779-9FBB729C-8D29-43F8-BA35-AC47ACFB815CQ47578102-B0A0ACFC-C1E4-4023-BD29-B93023612BD7Q48259698-D027A174-C3A2-4AA8-89DE-9068BA3F2C85Q49238507-1E08CB24-092D-4CDE-A8A0-25C5F736CB73Q49645938-3A524A4D-8249-41AB-B70C-C198E8DDAA9CQ50030501-5F30579B-4CF9-4774-AD38-454006F61ADBQ50115047-14518547-3BB0-4AF1-B176-4AFB9D57C8B6Q50915048-6AC22797-3EEA-4B02-9178-3774D3F5F91AQ52721830-E64E10BF-99E0-4E0B-92DC-847FE471A33AQ52769264-3858F6C7-2224-46D9-9D73-EFCAB37066C2
P2860
Efficacy, durability, and response predictors of low-dose interleukin-2 therapy for chronic graft-versus-host disease.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 12 April 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Efficacy, durability, and resp ...... nic graft-versus-host disease.
@en
Efficacy, durability, and resp ...... nic graft-versus-host disease.
@nl
type
label
Efficacy, durability, and resp ...... nic graft-versus-host disease.
@en
Efficacy, durability, and resp ...... nic graft-versus-host disease.
@nl
prefLabel
Efficacy, durability, and resp ...... nic graft-versus-host disease.
@en
Efficacy, durability, and resp ...... nic graft-versus-host disease.
@nl
P2093
P2860
P1433
P1476
Efficacy, durability, and resp ...... nic graft-versus-host disease.
@en
P2093
Carol G Reynolds
Corey S Cutler
David Avigan
Edwin P Alyea
Haesook T Kim
Jennifer Whangbo
Jerome Ritz
John Koreth
Joseph H Antin
Katherine Dusenbury
P2860
P304
P356
10.1182/BLOOD-2016-02-702852
P407
P577
2016-04-12T00:00:00Z